

## NEWS RELEASE



### **KDIGO Announces High Priority on Guideline Updates**

BRUSSELS, BELGIUM

Kidney Disease: Improving Global Outcomes (KDIGO) is pleased to announce an expansion of its guideline development program to include more frequent and rapid updates of KDIGO guidelines based on emerging evidence. KDIGO is actively reviewing guidelines to determine which need updating. When an update is needed, KDIGO will move expeditiously to secure a work group, appoint an independent evidence review team (ERT), and start the public comment process.

A work group is currently being selected for a formal update of the 2012 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD). A focused update of the 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in CKD is also underway. Ongoing surveillance for emerging evidence that could impact the Clinical Practice Guideline on Diabetes Management in CKD will begin early in 2021.

An ERT has been retained to alert KDIGO leadership and guideline Co-Chairs when relevant studies are published that could influence an existing guideline and warrant an update. When such evidence is found, the guideline work group will assess the impact of those studies and update the guideline as appropriate. KDIGO will continue to follow its rigorous guideline development processes when monitoring literature and updating guidelines. This is led by a volunteer work group and supported by a systematic literature review and evidence synthesis performed by an independent ERT.

The focused update of the KDIGO Hepatitis C in CKD Guideline will use the team from Brown University that developed the 2018 guideline. The Cochrane Kidney and Transplant ERT will coordinate evidence surveillance and assessment for potential updates to the three most recent KDIGO guidelines for Diabetes Management in CKD, Blood Pressure Management in CKD, and Glomerular Diseases.

Michel Jadoul, KDIGO Co-Chair and Co-Chair of the Hepatitis C Guideline, said, "I am pleased that KDIGO is responsive to scientific developments and is committed to making the latest evidence available to the global kidney community. This Hepatitis C process clearly illustrates that."

KDIGO will also employ MAGICapp, an authoring and publication platform for guidelines and evidence summaries developed by the MAGIC Evidence Ecosystem Foundation of Oslo, Norway. The Diabetes Management in CKD Guideline will be the first KDIGO guideline fully accessible on the MAGICapp platform.

KDIGO makes all guidelines and updates open access so that clinicians worldwide can obtain the most up-to-date information without charge. KDIGO publishes its guidelines in *Kidney International (KI)* for worldwide distribution in print. All KDIGO guidelines and future updates will be available on the *KI* website and the KDIGO website, along with implementation tools and materials developed to support the guidelines. KDIGO guidelines are also accessible on the KDIGO app, which is available for both Apple and Android phones.

"KDIGO is more committed than ever to keeping guidelines up-to-date," said Wolfgang Winkelmayr, MD, a Co-Chair of KDIGO. "Emerging new science must be made readily available. That is becoming a more important part of KDIGO's agenda as we develop guidelines on new topics in addition to renewing the existing library of KDIGO guidelines. We're excited to be a pioneer in this process and to act as a leader of guideline development in global nephrology."